Elicera Therapeutics AB (OSTO:ELIC) 3-Year EBITDA Growth Rate : -75.80% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Elicera Therapeutics AB 3-Year EBITDA Growth Rate?

Elicera Therapeutics AB's EBITDA per Share for the three months ended in Dec. 2023 was kr-0.24.

During the past 3 years, the average EBITDA Per Share Growth Rate was -75.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Elicera Therapeutics AB was -75.80% per year. The lowest was -359.90% per year. And the median was -217.85% per year.

Competitive Comparison of Elicera Therapeutics AB's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Elicera Therapeutics AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Elicera Therapeutics AB's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Elicera Therapeutics AB's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Elicera Therapeutics AB's 3-Year EBITDA Growth Rate falls into.

Elicera Therapeutics AB 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Elicera Therapeutics AB (OSTO:ELIC) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Elicera Therapeutics AB 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Elicera Therapeutics AB's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Elicera Therapeutics AB (OSTO:ELIC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Elicera Therapeutics AB (OSTO:ELIC) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

8E8:Germany

Address

Massans gata 10, World Trade Center Goteborg, 7th Floor, Goteborg, SWE, SE-412 51

Website

https://www.elicera.com

Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments. The company's product portfolio consists of four drug candidates, two in the field of oncolytic viruses (ELC-100 and ELC-201) and two in the field of CAR T-cell treatments (ELC-301 and ELC-401), in addition to a universal CAR T-cell technology platform, iTANK (ELC-001), compatible with any CAR T-cell therapy for a multi-targeted attack on solid tumors.

Elicera Therapeutics AB (OSTO:ELIC) Headlines

No Headlines